Seek Returns logo

PHG vs. RPRX: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at PHG and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

PHG trades as New York Registered Shares, providing U.S. investors with access to a foreign company, while RPRX is a standard domestic stock.

SymbolPHGRPRX
Company NameKoninklijke Philips N.V.Royalty Pharma plc
CountryNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Equipment & SuppliesPharmaceuticals
Market Capitalization26.43 billion USD21.51 billion USD
ExchangeNYSENasdaqGS
Listing DateMarch 17, 1980June 16, 2020
Security TypeNY Reg ShrsCommon Stock

Historical Performance

This chart compares the performance of PHG and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

PHG vs. RPRX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolPHGRPRX
5-Day Price Return1.54%1.04%
13-Week Price Return12.47%7.68%
26-Week Price Return-12.21%13.62%
52-Week Price Return-11.79%34.16%
Month-to-Date Return2.68%0.22%
Year-to-Date Return-2.79%44.57%
10-Day Avg. Volume1.10M3.37M
3-Month Avg. Volume1.84M4.10M
3-Month Volatility28.64%21.06%
Beta1.050.59

Profitability

Return on Equity (TTM)

PHG

-0.18%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

PHG has a negative Return on Equity of -0.18%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

RPRX

15.20%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

RPRX’s Return on Equity of 15.20% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

PHG vs. RPRX: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

PHG

0.90%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

Falling into the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Net Profit Margin of 0.90% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

RPRX

44.28%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

RPRX’s Net Profit Margin of 44.28% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

PHG vs. RPRX: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

PHG

6.11%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

PHG’s Operating Profit Margin of 6.11% is in the lower quartile for the Health Care Equipment & Supplies industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

RPRX

79.84%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

RPRX’s Operating Profit Margin of 79.84% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

PHG vs. RPRX: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolPHGRPRX
Return on Equity (TTM)-0.18%15.20%
Return on Assets (TTM)-0.08%5.66%
Net Profit Margin (TTM)0.90%44.28%
Operating Profit Margin (TTM)6.11%79.84%
Gross Profit Margin (TTM)43.85%--

Financial Strength

Current Ratio (MRQ)

PHG

1.26

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

PHG’s Current Ratio of 1.26 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RPRX

1.26

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

RPRX’s Current Ratio of 1.26 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

PHG vs. RPRX: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

PHG

0.81

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

PHG’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.81. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RPRX

1.26

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.26. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

PHG vs. RPRX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

PHG

1.41

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s Interest Coverage Ratio of 1.41 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

RPRX

4.70

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

PHG vs. RPRX: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolPHGRPRX
Current Ratio (MRQ)1.261.26
Quick Ratio (MRQ)0.811.26
Debt-to-Equity Ratio (MRQ)0.811.26
Interest Coverage Ratio (TTM)1.414.70

Growth

Revenue Growth

PHG vs. RPRX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

PHG vs. RPRX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

PHG

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

PHG’s Dividend Yield of 0.00% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.

RPRX

1.76%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

RPRX’s Dividend Yield of 1.76% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

PHG vs. RPRX: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

PHG

0.42%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

PHG’s Dividend Payout Ratio of 0.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RPRX

36.87%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

RPRX’s Dividend Payout Ratio of 36.87% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

PHG vs. RPRX: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolPHGRPRX
Dividend Yield (TTM)0.00%1.76%
Dividend Payout Ratio (TTM)0.42%36.87%

Valuation

Price-to-Earnings Ratio (TTM)

PHG

140.05

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

At 140.05, PHG’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

RPRX

21.00

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

RPRX’s P/E Ratio of 21.00 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

PHG vs. RPRX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

PHG

1.26

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

In the lower quartile for the Health Care Equipment & Supplies industry, PHG’s P/S Ratio of 1.26 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

RPRX

9.30

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 9.30, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

PHG vs. RPRX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

PHG

1.89

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

PHG’s P/B Ratio of 1.89 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

RPRX

3.19

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

RPRX’s P/B Ratio of 3.19 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

PHG vs. RPRX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolPHGRPRX
Price-to-Earnings Ratio (TTM)140.0521.00
Price-to-Sales Ratio (TTM)1.269.30
Price-to-Book Ratio (MRQ)1.893.19
Price-to-Free Cash Flow Ratio (TTM)14.6617.80